Based on clinical studies on dosing, efficacy, and pharmacokinetics, European authorities have recommended Celltrion's subcutaneous infliximab biosimilar (Remsima SC) for 5 new indications.
Celltrion Healthcare’s subcutaneous infliximab biosimilar (Remsima SC) has been recommended for approval for 5 new indications by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Already indicated for rheumatoid arthritis in Europe (November 2019), Remsima SC has been recommended for marketing authorization for ankylosing spondylitis, Crohn disease, ulcerative colitis (UC), psoriatic arthritis, and psoriasis. The infliximab biosimilar is marketed as Inflectra in the United States.
Studies Support Recommendations
Celltrion, based in Incheon, Republic of Korea, said the CHMP recommendations were supported by phase 1/3 studies that compared the pharmacokinetics, efficacy, and safety of the intravenous and SC formulations of Remsima in patients with Crohn disease and UC. CHMP has recommended a 120 mg dose of Remsima SC for the existing and additional 5 recommendations in adults regardless of body weight, based on the results.
Walter Reinisch, director of the Clinical IBD Study Group at Medical University of Vienna, Austria, said the SC formulation offers patients treatment flexibility during maintenance treatment with infliximab and “takes significantly less time than the current intravenous formulation, thereby reducing the time patients need to be in medical settings with infusion administrations.”
That observation takes on added significance against the backdrop of the coronavirus disease 2019 pandemic, he added, because patients “must take extra precautions and visit hospitals only when absolutely necessary.” The SC formulation can be administered by patients without assistance from health care professionals.
The clinical studies that supported the CHMP recommendation involved randomization of patients to varied doses of the SC formulation or continued intravenous (IV) administration.
Following loading doses of IV 5 mg/kg received at weeks 0 and 2, patients were randomised at week 6 to receive either SC 120 mg (<80 kg) or 240 mg (≥80 kg) every 2 weeks in the SC arm, or they were continued on IV 5 mg/kg every 8 weeks in the IV arm. Starting from week 30, patients in the IV 5 mg/kg cohort were switched to SC 120 mg or 240 mg, according to body weight, Celltrion said in a statement.
The Crohn Disease Activity Index and partial Mayo scores for UC disease activity decreased over time in both arms until week 30. Comparable improvement was seen in the remaining IV patients switched to SC formulation starting at week 30 of the trial. Celltrion said rates of clinical response and remission at week 54 were maintained, and mucosal healing in Crohn disease and UC continued to improve. Serum concentrations were comparable and consistent up to week 54, and the overall safety profile was comparable between SC and IV arms.
Remsima has been on the market for 5 years and now is available in over 90 countries, the company said. “If approved by the EMA, Remsima will be the first infliximab to have both intravenous and subcutaneous formulations to treat patients with ankylosing spondylitis, Crohn disease, ulcerative colitis, psoriatic arthritis and psoriasis,” Hyoung-Ki Kim, vice chairman, said in the statement.
Through regulatory filings, Celltrion hopes to obtain patent protection for the SC formulation and dosage through 2037 and 2038, respectively, in the United States, Europe, and Asia.
Earlier this month, Celltrion announced that its infliximab product will be tested in the CATALYST trial for its potential in controling cytokine release syndrome, which occurs in patients with COVID-19.
Late last year, Celltrion reported that as of the third quarter of 2018 its infliximab biosimilar had achieved a 56% share of the European market for infliximab.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.